We hope to see you again soon!
You are now leaving Lundbeck UK's website (www.lundbeck.com/uk) for an external website. External links are provided as a resource to the viewer. Lundbeck UK are not responsible for the external website and its content.
UK-NOTPR-1010 | April 2022
Pipeline
Therapies in development
Our research and development teams aim to target the underlying mechanisms of brain disease. We move together towards a singular goal to deliver therapies that redefine the standard of care for patients and address the areas in brain disease where we see the greatest unmet need.
| Project | Area | Phase 1 | Phase 2 | Phase 3 | Filing | ||
|---|---|---|---|---|---|---|---|
| Lu AF28996 (D1-D2 agonist)⁷ | Neurology | 1 | |||||
| Lu AF82422 (anti-alpha-synuclein mAb) | Neurology | 2 | |||||
| Lu-AF41156 (D2 agonist) | Psychiatry | Filing | |||||
| Lu AG13909 (anti-ACTH mAb)⁴ | Neurology | 1 | |||||
| Lu AG06466 (MAGL inhibitor) | Psychiatry + Neurology | 1 | |||||
| Lu AG22515 (CD40L blocker)⁹ | Neurology | 1 | |||||
| Lu AG09222 (anti-PACAP mAb)³ | Neurology | 2 |
| Project | Area | Phase 1 | Phase 2 | Phase 3 | Filing | ||
|---|---|---|---|---|---|---|---|
| Lu AF28996 (D1-D2 agonist)⁷ | Neurology | 1 | |||||
| Lu AF82422 (anti-alpha-synuclein mAb) | Neurology | 2 | |||||
| Lu-AF41156 (D2 agonist) | Psychiatry | Filing | |||||
| Lu AG13909 (anti-ACTH mAb)⁴ | Neurology | 1 | |||||
| Lu AG06466 (MAGL inhibitor) | Psychiatry + Neurology | 1 | |||||
| Lu AG22515 (CD40L blocker)⁹ | Neurology | 1 | |||||
| Lu AG09222 (anti-PACAP mAb)³ | Neurology | 2 |
* CD40L/serum-albumin bispecific antibody-fragment ((scFv)2-Fab)) based on AprilBio’s SAFA™ technology platform.
More from Lundbeck
Research and development
R&D of new and improved treatments is at the core of what we do.
Our position on brain health
What brain health means to us at Lundbeck.
Our commitment
We strive for Progress in Mind - our multifaceted approach to patients.
UK-NOTPR-2235| November 2024